Vanda Pharmaceuticals | VNDA - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 270.57M 450K 2026-09
Agios Pharmaceuticals USD 155.3M 24.53M 2026-06
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 1.11B 52.78M 2026-09
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 11.55B 674M 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Halozyme Therapeutics USD 198M 4.66M 2026-09
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 606.26M 79.46M 2026-09
J&J USD 18.93B 1.09B 2026-09
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
Ligand Pharmaceuticals USD 94.5M 39.4M 2026-09
Merck USD 10.75B 5.02B 2026-09
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Moderna USD 1.18B 223M 2026-09
Novartis USD 13.19B 3.9B 2026-09
Pfizer USD 89B 3.81B 2026-09
PTC Therapeutics USD 211.54M 15.12M 2026-06
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 598M 2026-09
Takeda JPY 981.78B 36.71B 2026-09
Teva Pharmaceutical Industries USD 3.18B 733M 2026-09
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12
Veracyte USD 133.73M 7.37M 2026-09